Company profile
Actuate Therapeutics, Inc.
Pipeline1 asset
- elraglusib9-ING-41 / GSK-3β / small molecule inhibitor / Oncology1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 2ongoing; Actuate-1801 Part 3BUSEUCanada1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 3in planning; registration trial contingent on funding1L metastatic pancreatic cancer with FOLFIRINOXPhase 2investigator-initiated; closed to enrollment
Latest news4 items
All news2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Presentation / Abstract • Phase 2ASCO abstract release Mon, Jun 1, 2026